

Amendments to the Claims:

This listing of claims as required by 37 C.F.R. 1.121 will replace all prior versions and listing of claims in the application.

1-25. (Cancelled)

26. (Currently Amended) A method for generating an immune response in a patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5'-pyrimidine-purine-3', wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside ~~an oligonucleotide analog immunostimulatory compound according to any one of claims 1, 2, 9, 12, and 20.~~
27. (Original) The method according to claim 26, wherein the oligonucleotide analog immunostimulatory compound is administered in combination with an antibiotic, antigen, allergen, vaccine, antibody, cytotoxic agent, antisense oligonucleotide, gene therapy vector, DNA vaccine, adjuvant, or combination thereof.
28. (Original) The method according to claim 26, wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.
29. (Original) The method according to claim 28, wherein such conjugation is to the 3'-end of the oligonucleotide compound.

30. (Currently Amended) A method for therapeutically treating a patient having disease caused by a pathogen, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5'-pyrimidine-purine-3', wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside ~~an immunostimulatory oligonucleotide compound according to any of claims 1, 2, 9, 12, and 20.~~
31. (Original) The method according to claim 30, wherein the pathogen is a virus.
32. (Original) The method according to claim 30, wherein the pathogen is a parasite.
33. (Original) The method according to claim 30, wherein the pathogen is a bacterium.
34. (Currently Amended) A method for treating a cancer patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5'-pyrimidine-purine-3', wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside ~~an immunostimulatory oligonucleotide compound according to any of claims 1, 2, 9, 12, and 20.~~
35. (Original) The method according to claim 34, wherein the immunostimulatory oligonucleotide compound is administered in combination with a chemotherapeutic compound.

36. (Currently Amended) A method for treating an autoimmune disorder, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5'-pyrimidine-purine-3', wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside ~~an oligonucleotide analog immunostimulatory compound according to any of claims 1, 2, 9, 12, and 20.~~
37. (Original) The method according to claim 36, wherein the autoimmune disorder is autoimmune asthma.
38. (Currently Amended) A method for treating airway inflammation or allergy, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5'-pyrimidine-purine-3', wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside ~~an oligonucleotide analog immunostimulatory compound according to any of claims 1, 2, 9, 12, and 20.~~